Pacemaker és implantálható cardioverter defibrillátor kezelés legújabb eredményei

Translated title of the contribution: Treatment with pacemaker and implantable cardioverter defibrillators - New results

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Device-based anti-arrhythmic therapy is one of the most dinamically evolving branches of the medicine. Brady- and tachyarrhythmias can be treated efficiently and cost-effective with current pacemakers and ICDs. Beside conventional indications new indications have appeared in the last years: resynchronization treatment of severe congestive heart failure with biventricular pacing, primary prevention of sudden cardiac death with ICD, reduction of intraventricular gradient in hypertrophic obstructive cardiomyopathy. Several large clinical studies have investigated the efficacy of treatment in conventional indications, so the role of pacemaker therapy in carotid sinus hyperaesthesia or sinus node disease has been elucidated. Newer studies are trying to clarify the type or programming of the pacemaker in a given indication: physiological pacemakers have a more beneficial effect on the quality of life and decrease the incidence of atrial fibrillation. The implanted devices have frequency adaptation with new sensors, and they are even able to detect heart failure in an early phase. In the near future the number of pacemaker and ICD implantations will grow exponentially based on current trend. This will be due to the aging population, the simplification and increasing safety of implantation, and the widening of the indications for antiarrhythmic device implantation.

Original languageHungarian
Pages (from-to)1088-1098
Number of pages11
JournalOrvosi Hetilap
Volume146
Issue number20 SUPPL. 2
Publication statusPublished - 2005

Fingerprint

Implantable Defibrillators
Equipment and Supplies
Heart Failure
Hyperesthesia
Sick Sinus Syndrome
Carotid Sinus
Cardiac Resynchronization Therapy
Anti-Arrhythmia Agents
Hypertrophic Cardiomyopathy
Sudden Cardiac Death
Primary Prevention
Bradycardia
Tachycardia
Atrial Fibrillation
Therapeutics
Quality of Life
Medicine
Safety
Costs and Cost Analysis
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pacemaker és implantálható cardioverter defibrillátor kezelés legújabb eredményei. / Merkely, B.

In: Orvosi Hetilap, Vol. 146, No. 20 SUPPL. 2, 2005, p. 1088-1098.

Research output: Contribution to journalArticle

@article{6e794862573a439590faf7ce56c5bc31,
title = "Pacemaker {\'e}s implant{\'a}lhat{\'o} cardioverter defibrill{\'a}tor kezel{\'e}s leg{\'u}jabb eredm{\'e}nyei",
abstract = "Device-based anti-arrhythmic therapy is one of the most dinamically evolving branches of the medicine. Brady- and tachyarrhythmias can be treated efficiently and cost-effective with current pacemakers and ICDs. Beside conventional indications new indications have appeared in the last years: resynchronization treatment of severe congestive heart failure with biventricular pacing, primary prevention of sudden cardiac death with ICD, reduction of intraventricular gradient in hypertrophic obstructive cardiomyopathy. Several large clinical studies have investigated the efficacy of treatment in conventional indications, so the role of pacemaker therapy in carotid sinus hyperaesthesia or sinus node disease has been elucidated. Newer studies are trying to clarify the type or programming of the pacemaker in a given indication: physiological pacemakers have a more beneficial effect on the quality of life and decrease the incidence of atrial fibrillation. The implanted devices have frequency adaptation with new sensors, and they are even able to detect heart failure in an early phase. In the near future the number of pacemaker and ICD implantations will grow exponentially based on current trend. This will be due to the aging population, the simplification and increasing safety of implantation, and the widening of the indications for antiarrhythmic device implantation.",
keywords = "Cardiac resynchronization therapy, Heart failure, Implantable cardioverter-defibrillator, Pacemaker, Sudden cardiac deat",
author = "B. Merkely",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1088--1098",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "20 SUPPL. 2",

}

TY - JOUR

T1 - Pacemaker és implantálható cardioverter defibrillátor kezelés legújabb eredményei

AU - Merkely, B.

PY - 2005

Y1 - 2005

N2 - Device-based anti-arrhythmic therapy is one of the most dinamically evolving branches of the medicine. Brady- and tachyarrhythmias can be treated efficiently and cost-effective with current pacemakers and ICDs. Beside conventional indications new indications have appeared in the last years: resynchronization treatment of severe congestive heart failure with biventricular pacing, primary prevention of sudden cardiac death with ICD, reduction of intraventricular gradient in hypertrophic obstructive cardiomyopathy. Several large clinical studies have investigated the efficacy of treatment in conventional indications, so the role of pacemaker therapy in carotid sinus hyperaesthesia or sinus node disease has been elucidated. Newer studies are trying to clarify the type or programming of the pacemaker in a given indication: physiological pacemakers have a more beneficial effect on the quality of life and decrease the incidence of atrial fibrillation. The implanted devices have frequency adaptation with new sensors, and they are even able to detect heart failure in an early phase. In the near future the number of pacemaker and ICD implantations will grow exponentially based on current trend. This will be due to the aging population, the simplification and increasing safety of implantation, and the widening of the indications for antiarrhythmic device implantation.

AB - Device-based anti-arrhythmic therapy is one of the most dinamically evolving branches of the medicine. Brady- and tachyarrhythmias can be treated efficiently and cost-effective with current pacemakers and ICDs. Beside conventional indications new indications have appeared in the last years: resynchronization treatment of severe congestive heart failure with biventricular pacing, primary prevention of sudden cardiac death with ICD, reduction of intraventricular gradient in hypertrophic obstructive cardiomyopathy. Several large clinical studies have investigated the efficacy of treatment in conventional indications, so the role of pacemaker therapy in carotid sinus hyperaesthesia or sinus node disease has been elucidated. Newer studies are trying to clarify the type or programming of the pacemaker in a given indication: physiological pacemakers have a more beneficial effect on the quality of life and decrease the incidence of atrial fibrillation. The implanted devices have frequency adaptation with new sensors, and they are even able to detect heart failure in an early phase. In the near future the number of pacemaker and ICD implantations will grow exponentially based on current trend. This will be due to the aging population, the simplification and increasing safety of implantation, and the widening of the indications for antiarrhythmic device implantation.

KW - Cardiac resynchronization therapy

KW - Heart failure

KW - Implantable cardioverter-defibrillator

KW - Pacemaker

KW - Sudden cardiac deat

UR - http://www.scopus.com/inward/record.url?scp=22144451855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144451855&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 1088

EP - 1098

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 20 SUPPL. 2

ER -